TRON stock delisting risk rises as shares sit 15 cents above Nasdaq’s $1 threshold
TRON’s stock faces a delisting risk as its decline leaves it just 15 cents above $1, Nasdaq’s minimum listing-price threshold. As of October 19, 2026, TRON Inc. remained above that level, while its market capitalization was roughly twice the approximate value of its cryptocurrency holdings.
Summary
Key takeaways
- Nasdaq’s $1 threshold is close to TRON Inc.’s share price.
- A sustained breach would trigger a 180-day compliance period.
- TRON Inc.’s TRX holdings are worth just over $250 million.
Nasdaq rules define TRON stock’s delisting risk
TRON Inc. would enter a 180-day compliance period if its shares closed below $1 for 30 consecutive trading days. After that period, the stock would become eligible for delisting from Nasdaq.
The shares are still above the threshold. Their proximity to it follows a continuing decline despite the company’s regular, small purchases of additional TRX.
A treasury business valued above its TRX holdings
TRON Inc.’s publicly listed wallet shows just over $250 million in TRX, compared with a market capitalization of over $500 million. That puts the company’s equity valuation at roughly twice the value of those token holdings.
The business operates as a cryptocurrency treasury company: it buys, holds and stakes TRON cryptocurrency. Its activities also include purchasing older intellectual property and selling children’s toys and accessories.
Justin Sun keeps promoting the company
Justin Sun continues to promote TRON Inc. despite its limited business activities and falling share price. The company has continued making modest token purchases, but the stock’s decline has persisted alongside those purchases and Sun’s promotion.
TRON stock’s delisting risk hinges on the price-and-duration conditions in Nasdaq’s rules. At the October 19 snapshot, the shares remained 15 cents above the $1 threshold.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475
Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million
Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.
Dow Jones Top Markets Headlines at 3 AM ET: Asian Stocks Mixed as AI Spending Concerns Linger | U.S. ...
The Top 15 Stocks in the S&P 500 Are Now 47% of the Value. In 2000 Bubble, It Was 27%

